Gastroenteritis Clinical Trial
Official title:
Pilot Study of Omalizumab in Eosinophilic Gastroenteritis
Verified date | December 23, 2008 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the safety and usefulness of omalizumab (anti-IgE, Xolair) in
reducing eosinophil counts and improving symptoms in patients with eosinophilic
gastroenteritis (EG). EG is a disorder of unknown cause in which eosinophils, a type of white
blood cell, are increased in the blood and gut tissue. Patients with EG have symptoms like
stomach pain, bloating, and vomiting. About 50 percent of EG patients have food or
environmental allergies, which may play a role in EG. Some patients with EG improve
significantly on diets avoiding foods to which they are allergic. Immunoglobulin E (IgE) is
an antibody that plays an important role in initiating allergic reactions. Omalizumab is a
monoclonal antibody directed against IgE. The Food and Drug Administration approved
omalizumab in 2003 for treating patients 12 years of age and older with allergic asthma.
Patients between 12 and 76 years of age with eosinophilic gastroenteritis who have a blood
eosinophil count of 500 or more and who have a food allergy or allergy to an inhaled allergen
may be eligible for this study. Candidates are screened with a medical history, physical
examination, and blood and urine tests.
Participants undergo the following procedures:
- Leukapheresis. This procedure is done to collect quantities of white blood cells to
study the effects of omalizumab on eosinophils and other immune substances. Blood flows
from a needle placed in an arm vein through a catheter (plastic tube) into a machine
that separates the blood into its components by centrifugation (spinning). Some of the
white cells are removed and the rest of the blood (red cells, plasma and platelets) is
returned to the body through a needle in the other arm.
- Skin testing. Participants are tested for allergies to specific substances. A small
amount of various allergens (substances that cause allergies) are placed on the
subject's arm. The skin is pricked at the sites of the allergens and the skin reaction
after several minutes is observed.
- Upper and lower endoscopy. One or both of these procedures is done, depending on the
part of the gastrointestinal tract that is involved, to examine the tract. If both
procedures are done, they are performed at the same time. For the upper endoscopy, the
subject's throat is sprayed with a numbing medicine and a long, flexible tube is passed
through the esophagus, stomach and small intestine. For the lower endoscopy, the tube is
passed through the rectum into t...
Status | Completed |
Enrollment | 30 |
Est. completion date | February 5, 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 76 Years |
Eligibility |
-INCLUSION CRITERIA: 1. All Subjects must be at least 12 years of age and no older than 76 years of age. 2. All subjects must meet the established diagnostic criteria for eosinophilic gastroenteritis: gastrointestinal symptoms, histologic evidence of gastrointestinal tissue infiltration by eosinophils with greater than or equal to 25 eosinophils per high powered field, no known etiology for the eosinophilia despite careful clinical evaluation. 3. Eosinophilia greater than 500/mm3 at screening. 4. Baseline values within the following laboratory ranges: - White blood cell count greater than or equal to 3,300 cells/uL - Absolute neutrophil count greater than or equal to 1,000 cells/uL - Hemoglobin greater than or equal to 10 g/dL - Platelet count greater than or equal to 100,000 platelets uL 5. Evidence of atopy as defined by one of the following: - Skin testing - RAST testing - Serum IgE greater than or equal to100 6. Women of childbearing potential only: negative serum Beta-hCG. 7. Agree to practice abstinence or effective contraception from initiation of the protocol and for 3 months following the last infusion of the study drug (effective contraception methods include abstinence, surgical sterilization of either partner, barrier methods such as diaphragm, condom, cap, or sponge, or hormonal contraception). 8. Weight (Kg) x serum IgE (IU/mL) less than or equal to 63,000 (per dosing restrictions). 9. Stable corticosteroid dose for one month prior to screening and willingness to continue on that dose for the first 16 weeks of the study. 10. Subjects (guardians for younger patients) must be able to give informed consent (or assent as appropriate). EXCLUSION CRITERIA: 1. Pregnant or nursing women. 2. HIV positive or other known immunodeficiency. 3. Use of any other investigational agent within 30 days of the study. 4. Presence of FIP1-PDGF-R fusion gene. 5. Any condition that, in the investigator's opinion, places the patient at undue risk by participating in the study. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Kelly KJ. Eosinophilic gastroenteritis. J Pediatr Gastroenterol Nutr. 2000;30 Suppl:S28-35. Review. — View Citation
Lee M, Hodges WG, Huggins TL, Lee EL. Eosinophilic gastroenteritis. South Med J. 1996 Feb;89(2):189-94. — View Citation
Park HS, Kim HS, Jang HJ. Eosinophilic gastroenteritis associated with food allergy and bronchial asthma. J Korean Med Sci. 1995 Jun;10(3):216-9. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of safety of omalizumab and its efficacy in reducing peripheral blood absolute eosinophil count pre- and post-omalizumab administration. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01168401 -
Bivalent Norovirus Vaccine Study
|
Phase 1 | |
Completed |
NCT02541695 -
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
|
N/A | |
Completed |
NCT02473887 -
Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting
|
Phase 1 | |
Completed |
NCT01911143 -
A Retrospective, Blinded Validation of a Host-response Based Diagnostics
|
N/A | |
Not yet recruiting |
NCT01671137 -
Probiotic for the Prevention of Functional Disorders in Childhood
|
N/A | |
Completed |
NCT01917461 -
Observational, Prospective Clinical Study to Evaluate Biomarkers as Indicators of Acute Bacterial or Viral Infections
|
N/A | |
Withdrawn |
NCT00691275 -
Efficacy Study of IV Fluids Only vs Ondansetron to Treat Dehydration
|
N/A | |
Recruiting |
NCT06025695 -
Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks
|
Phase 3 | |
Completed |
NCT04463082 -
Non-invasive Assessment of the Current State of Hydration in Children by Ultrasound
|
N/A | |
Completed |
NCT02497417 -
A Multi-Site Clinical Evaluation of the ARIES Clostridium Difficile Assay in Symptomatic Patients
|
N/A | |
Active, not recruiting |
NCT03000296 -
Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease
|
N/A | |
Completed |
NCT01225042 -
The Effect of Probiotics on E. Coli Gastroenteritis
|
N/A | |
Completed |
NCT01236066 -
Impact of Rotavirus Vaccination on Hospitalisations for Rotavirus Gastroenteritis in Children Aged <5 Years in Australia
|
N/A | |
Recruiting |
NCT00987519 -
Viral Respiratory and Gastrointestinal Infections in Children Under 6 Years of Age
|
N/A | |
Terminated |
NCT01357174 -
ROTATEQâ„¢ Post-Marketing Surveillance in the Philippines
|
N/A | |
Completed |
NCT01033799 -
Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers
|
N/A | |
Recruiting |
NCT01363726 -
Surveillance of Rotavirus Gastroenteritis in Children <5 Years
|
N/A | |
Completed |
NCT00130832 -
Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)
|
Phase 3 | |
Terminated |
NCT02568189 -
Utility of Ultrasound Assessment of the Inferior Vena Cava in Patients With Sepsis and Dehydration
|
N/A | |
Terminated |
NCT02165813 -
Oral Nitazoxanide in Acute Gastroenteritis in Australian Indigenous Children
|
Phase 2/Phase 3 |